Cargando…

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer

(1) Background: At present, the efficacy and safety of thoracic radiotherapy (TRT) after chemo-immunotherapy (CT-IT) in patients with extensive-stage small-cell lung cancer (ES-SCLC) still remain unclear. The purpose of this study was to evaluate the role of TRT after CT-IT in patients with ES-SCLC....

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Zhaoliang, Liu, Jingru, Wu, Min, Wang, Xiaohan, Lu, Yuhan, Han, Chunyan, Cong, Lei, Li, Jisheng, Meng, Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253710/ https://www.ncbi.nlm.nih.gov/pubmed/37298023 http://dx.doi.org/10.3390/jcm12113828

Ejemplares similares

What is the role of consolidative thoracic radiotherapy in the era of chemo-immunotherapy for extensive stage small cell lung cancer?
por: Higgins, Kristin A., et al.
Publicado: (2020)

Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis
por: Cai, Zijing, et al.
Publicado: (2023)

Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
por: Peng, Jianfeng, et al.
Publicado: (2023)

The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer
por: Verma, Saurav, et al.
Publicado: (2023)

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
por: Sathiyapalan, Arani, et al.
Publicado: (2022)

Consolidative thoracic radiotherapy for extensive stage small cell lung cancer
por: Zhang, Xiaoli, et al.
Publicado: (2017)

Is consolidative thoracic radiotherapy of extensive-stage small cell lung cancer still beneficial in the era of immunotherapy? A retrospective analysis
por: Hoffmann, Elgin, et al.
Publicado: (2023)

A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer
por: Qiu, Guihuan, et al.
Publicado: (2023)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
por: Grambozov, Brane, et al.
Publicado: (2022)

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice
por: Yang, Yaning, et al.
Publicado: (2022)

Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not?
por: Luo, Jing, et al.
Publicado: (2017)

Role of thoracic radiotherapy in extensive stage small cell lung cancer: a systemic review and meta-analysis
por: Li, Ao-Mei, et al.
Publicado: (2021)

A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Lara-Velazquez, Montserrat, et al.
Publicado: (2021)

Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies
por: Genard, Géraldine, et al.
Publicado: (2017)

Real-World Effectiveness and Prognostic Factors Analysis of Stages I–III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy
por: Liu, Zuo, et al.
Publicado: (2021)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases
por: Moyers, Justin T., et al.
Publicado: (2021)

Bio-chemo-mechanics of the thoracic aorta
por: Iddawela, Sashini, et al.
Publicado: (2021)

Chemo-immunotherapy by dual-enzyme responsive peptide self-assembling abolish melanoma
por: Wang, Yuhan, et al.
Publicado: (2023)

Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis
por: Qi, Jing, et al.
Publicado: (2019)

Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy
por: Wang, Yang, et al.
Publicado: (2023)

Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy
por: Yu, Xin, et al.
Publicado: (2021)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study
por: Tomono, Hiromi, et al.
Publicado: (2023)

Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series
por: Diamond, Brett H., et al.
Publicado: (2021)

Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer
por: Xu, Li-Ming, et al.
Publicado: (2017)

Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
por: Kim, Soo Han, et al.
Publicado: (2023)

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
por: Onn, Amir, et al.
Publicado: (2021)

Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations
por: Han, Jinmin, et al.
Publicado: (2021)

Concurrent chemo-radiotherapy with proton therapy: reduced toxicity with comparable oncological outcomes vs photon chemo-radiotherapy
por: Baumann, Brian C., et al.
Publicado: (2020)

Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma
por: Benasso, M, et al.
Publicado: (2000)

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
por: Son, Christine, et al.
Publicado: (2023)

Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study
por: Wu, Xiaoyue, et al.
Publicado: (2022)

A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy
por: Yuan, Xun, et al.
Publicado: (2021)

The need to optimize chemotherapy regimens for chemo-immunotherapy
por: Inamura, Kentaro, et al.
Publicado: (2022)

Real-World Evaluation of Modern Adjuvant Radiotherapy in Women with Stage IB Endometrial Cancer
por: Chen, Jenny Ling-Yu, et al.
Publicado: (2021)

Fasting Enhances the Response of Glioma to Chemo- and Radiotherapy
por: Safdie, Fernando, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dd5secs0kj3o8uca0ik3s1kk3a